Vacciguard Novel Vaccines

Lung cancer is the third most common cancer and the most common cause of cancer-related deaths in both men and women. According to the American National Cancer Institute (NCI), there were 213,380 estimated new cases of lung cancer and 160,390 deaths in the United States in 2007.

Due to its high reccurrence rate, the five-year survival rate is 15%, in comparison to 88% for breast cancer and 99% for prostate cancer. This low survival rate points to a clear medical need and high market potential for effective therapies to combat the disease.

VacciGuard's vaccines are a promising candidate for significantly reducing the rate of recurrence in lung cancer patients.